Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
INDIANAPOLIS, Jan. 04, 2018 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that Derek Small, Assembly’s chief executive officer, will present an overview of the company on Thursday, January 11th at 10:30 a.m. PT at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
A live audio webcast of the presentation will be available at investor.assemblybio.com. An archived replay of the webcast will be available for 30 days.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
[email protected]
Media:
Barbara Lindheim
(212) 584-2276
[email protected]
